UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II Patent applications |
Patent application number | Title | Published |
20150353643 | ANTI-CD277 ANTIBODIES AND USES THEREOF - Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vγ9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described. | 12-10-2015 |
20140322235 | ANTI-CD277 ANTIBODIES AND USES THEREOF - The present invention relates to anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vy9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The invention also relates to the use of said antibodies in therapy. | 10-30-2014 |
20140286996 | Modified Gram-Negative Bacteria For Use As Vaccines - The invention relates to Gram-negative bacteria carrying an inactivated gene encoding a glycosyltransferase involved in the synthesis of the core of the LPS of said Gram-negative bacteria, wherein said inactivated gene results in the synthesis of a LPS having a modified core. These strains have an attenuated virulence but induce a humoral immunity sufficient for ensuring vaccination of the host. | 09-25-2014 |
20140234342 | NKP46-MEDIATED NK CELL TUNING - The present invention relates to compounds (e.g. antibodies) that specifically bind and inhibit NKp46. Such compounds are capable, when administered to a mammal, capable of increasing the frequency of reactive and/or active NK cells. The invention also relates to pharmaceutical composition and methods of using the antibodies and compositions to treat or prevent diseases, e.g. cancer, infection, autoimmune diseases, inflammatory diseases and the like. | 08-21-2014 |
20130309252 | ANTAGONISTS OF GRASP55 FOR USE AS A MEDICAMENT - The present invention concerns antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55), for use as a medicament, in particular for use in the treatment of cell adhesion molecules implicated diseases, notably, MCAM or JAMs implicated diseases. According to some embodiments, said antagonists of the Golgi reassembly-stacking protein of 55 k Da (Grasp55) may be used in the treatment of cancer, metastases, and inflammatory diseases. The present invention further provides methods for screening for compounds liable of treating or preventing such diseases. | 11-21-2013 |
20130164268 | REGULATION OF GLYPICAN 4 ACTIVITY TO MODULATE THE FATE OF STEM CELLS AND USES THEREOF - The present invention thus relates to stem cells or progenitor cells wherein the expression and/or activity of a member of the glypican family is reduced or abolished for use for the treatment of a pathological condition selected from the group consisting of a degenerative disease, a cardiac disorder, a metabolic disease and an injury by stem cell-based therapy. | 06-27-2013 |
20130149306 | Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents - The present invention is related to the treatment of certain cancers using antagonists of the binding between a Plexin and a Sema3E. The invention may be helpful in treating primary cancer cell development and metastasis development wherein Sema3E is expressed, in particular overexpressed by the tumoral cells or the stroma. Breast cancer, in particular with distant metastases is concerned. Prostate cancer, melanoma and glioblastoma are also concerned. The antagonist may be any molecule that specifically binds to PlexinD1 or Sema3E and blocks the Sema3E/PlexinD1 binding. In an embodiment, the antagonist is a polypeptide or an antibody. | 06-13-2013 |
20120252012 | METHOD FOR DETECTING PROKARYOTIC DNA FROM A FECES SAMPLE - The present invention concerns a method of detection and preferably of quantification of DNA, preferably comprising prokaryotic DNA, extracted from a stool sample of an individual, especially for the molecular determination of the composition of the intestinal flora in the stool. According to the invention, one controls the quality of the DNA extraction by verifying whether one detects a specific DNA of | 10-04-2012 |
20120141365 | AMINO CATALYZED PRODUCTION OF HYDROGEN FROM SILYLATED DERVIVATIVES AS HYDROGEN CARRIER - A method for producing hydrogen comprising the steps of: i) contacting a compound (C) comprising one or more groups Si—H with an amine based catalyst in a solvent selected from an alcohol or an aqueous solution, thereby forming hydrogen and a by-product (C1); wherein said amine based catalyst is as defined in claim | 06-07-2012 |
20110311439 | NEW PROCESS OF PRODUCTION OF HYDROGEN FROM SILYLATED DERIVATIVES AS HYDROGEN CARRIER - A method for producing hydrogen (H | 12-22-2011 |
20110293634 | ANTIBODIES BINDING TO ADRENOMEDULLIN RECEPTORS AND USES THEREOF AS DRUGS - The invention relates to antibodies binding to the proteins forming adrenomedullin receptors, and to the uses thereof as a drug. | 12-01-2011 |
20110262960 | MYCOBACTERIA CULTURE MEDIUM AND METHOD INCLUDING MYCOBACTERIA OF MYCOBACTERIUM TUBERCULOSIS COMPLEX - The present invention relates to a novel mycobacteria culture medium, particularly for mycobacteria of the | 10-27-2011 |
20110165092 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION - The subject matter of the invention is a cosmetic and/or dermatological composition for use in the treatment of skin and/or hair disorders. More particularly, the invention relates to a cosmetic and/or dermatological composition comprising an inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, an inhibitor of farnesyl pyrophosphate synthase, or an inhibitor of one of the physiologically acceptable salts thereof and a cosmetic and/or dermatological product. The present invention finds, for example, a very advantageous use in the treatment of the effects of early ageing, in particular in terms of the skin and the hair system. | 07-07-2011 |
20110056543 | HYBRID NANOCOMPOSITE - The invention aims at a hybrid nanocomposite material comprising electrically conducting inorganic elongated nanocrystals grafted on at least part of the surface thereof with an electrically conducting organic compound, and a preparation process thereof. The invention further discloses thin films, solar cells and switchable devices comprising said hybrid nanocomposite. | 03-10-2011 |
20100301224 | X-ray imaging device having a polychromatic source - An X-ray imaging device includes a polychromatic X-ray source ( | 12-02-2010 |
20100075306 | METHOD FOR DIAGNOSIS OF AND FOLLOWING A BACTERIAL VAGINOSIS BY MOLECULAR QUANTIFICATION - The present invention relates to a method for in vitro diagnosis and follow-up of vaginal bacterial flora status in relation to the presence of bacterial vaginosis, and for monitoring its treatment where applicable, wherein the presence of bacterial vaginosis or failure of on-going treatment is determined if the concentrations of specific sequences present in a single copy in the DNA of the bacteria | 03-25-2010 |
20090105131 | USE OF POLY-ALPHA2,8-SIALIC ACID MIMETIC PEPTIDES TO MODULATE NCAM FUNCTIONS - The invention relates to the use of a peptide consisting of 5 to 30 amino acid residues, preferably 9 to 15, most preferably about 12 amino acid residues, said peptide comprising a B epitope of a poly-α2,8 sialic acid attached to NCAM, which is recognized by an anti-poly-α2,8 sialic acid (PSA) antibody, for the preparation of a medicament for modulating NCAM functions, to be administered for the prevention and/or the treatment of neurodegenerative diseases, brain and spine lesions, age-related learning and memory problems, and cancer. | 04-23-2009 |